Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

Spyre Therapeutics, Inc.

First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.
Preclinical data at UEGW shows comparable potency to risankizumab with >3x half-life extension in NHPs (~30 days).
Licensed IL-23 antibodies from Paragon for up to $22M in development/regulatory milestones plus low single-digit royalties.
Portfolio includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.
Combination data shows synergy of anti-IL-23 with anti-TL1A or anti-α4β7 in reducing IL-17 and inflammation in models.

item 1.01 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-24-237150
form_type: 8-K
ticker: SYRE
cik: 0001636282
company_name: Spyre Therapeutics, Inc.
filed_at: 2024-10-15T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.057490+00:00
generated_at: 2026-05-30T14:36:24.091071+00:00
sec_items: ["1.01", "7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-24-237150
json_url: https://secwatch.observer/filing/0001193125-24-237150.json
markdown_url: https://secwatch.observer/filing/0001193125-24-237150.md
text_url: https://secwatch.observer/filing/0001193125-24-237150.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/0001193125-24-237150-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524237150/d858952d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 1.01, 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIRJ

AirJoule Technologies raises $15M in registered direct offering at $4.10/share

AirJoule Technologies Corp. June 1, 2026, 8:34 AM ET other_material Items 1.01, 5.07, 7.01, 9.01

same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TMQ

Trilogy Metals extends closing date for $35.6M DOW investment to July 31, 2026

Trilogy Metals Inc. June 1, 2026, 7:09 AM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-24-237150

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.